PEAT Act of 2026
Apr 30, 2026
Introduced: Apr 30, 2026
Apr 30, 2026
Introduced: Apr 30, 2026
Summary
Stops a medicine from being classified as a 'biological product' only because it contains a protein that has no medical effect.
What problem does this solve?
Some medicines risk being reclassified as more complex 'biological products' just because they contain inactive proteins, which could make them more expensive. This bill prevents that reclassification, ensuring these drugs remain accessible to patients who need them.
What does this bill do?
Reference
Text:
Section:
Sec. 2(a)(2)
Header:
Prohibition with respect to treatment of proteins in biologics
Prevents reclassification of certain biologics
Amends the Public Health Service Act to state that a biologic cannot be treated as a 'biological product' just because it contains a protein that is a clinically inactive component.
Makes a technical correction
Corrects a punctuation error in the Public Health Service Act, changing 'protein ,' to 'protein,'.
Who does this affect?
- Patients with thyroid conditions
- Pharmaceutical manufacturers
- Pharmacists
What is the real world impact?
•
Ensures continued access to affordable medication
Prevents certain drugs, like some thyroid medications, from being reclassified in a way that could make them more expensive or harder for patients to obtain from their local pharmacy.
•
Reduces regulatory burden for drug manufacturers
Allows certain drugs containing proteins to avoid the stricter and more costly approval process required for 'biological products', which benefits manufacturers by keeping their products on the market with less regulation.
When does this start?
This bill would take effect as soon as it is signed into law.